Good morning, HealthTech insiders. A Paris biotech just raised $34 million to do something most AI drug-discovery companies cannot: grow patients' tumors in the lab, test cancer drugs against them, and predict how those treatments might perform in clinical trials. Its early model forecasts came within 0.82 months of published survival results across 32 trial arms. The findings are not yet peer-reviewed, but the approach points to a different kind of advantage in oncology.
And that is only one of three significant bets in today's Signal. Abridge is bringing each hospital's own clinical pathways into its AI assistant, while Ohio State is partnering with Microsoft to connect hospital operations, clinical data and research on one cloud platform.
In today's Signal:
Orakl Oncology raises $34M to scale lab-grown patient tumors and AI-powered predictions of cancer trial outcomes.
Abridge adds local clinical pathways to its AI assistant, bringing hospital-specific guidance into clinicians' workflows.
Ohio State and Microsoft sign a five-year deal to build a smart hospital and move 70–80% of computing and storage to Azure.
Plus: Abbott's new defibrillation lead, J&J's investment in Francis Medical, and R1's expanded revenue cycle AI.
In partnership with
Yes, that Arnold Schwarzenegger.
He has a newsletter on beehiiv. So do Codie Sanchez, Jay Shetty, David Begnaud, Colin & Samir, and Joanna Stern.
They could publish just about anywhere. They chose beehiiv to build a direct connection with the people who want to hear from them most. And you can do the same, whether you’re world-famous or just at the start of your plan for world domination.
LATEST DEVELOPMENTS
BIOTECH
1. Orakl Oncology Raises $34M to Predict Cancer Trial Results From Lab-Grown Patient Tumors
Orakl Oncology raised $34 million to expand its AI-powered platform for predicting cancer drug responses using patient-derived tumor models. Image: Norrsken VC.
Paris-based Orakl Oncology announced an oversubscribed $34 million Series A on November 12, co-led by Norrsken VC and Singular, bringing total funding to $50 million. The company combines patient-derived tumor organoids, drug testing and AI to forecast treatment outcomes before expensive clinical trials begin.
The details:
The evidence: Its SCOPE preprint predicted progression-free survival across 32 trial arms with an average error of 0.82 months (R² = 0.85), correctly ranking the better treatment in 7 of 8 comparisons. The study used 81 organoid lines and has not been peer-reviewed.
Commercial traction: Orakl says 18 of the top 20 pharmaceutical companies are in its pipeline, with multiyear collaborations spanning more than 10 drug programs. It also holds rights to evaluate four Sanofi oncology assets.
What's next: The funding will increase lab data production fivefold, expand into lung and gastric cancers, establish U.S. and UK teams, and support earlier-stage drug discovery.
The Signal: Drug-discovery AI has helped researchers design molecules faster, but Phase 2 failure remains expensive. Orakl is targeting a harder problem: predicting whether those molecules will work in patients. If prospective results hold up, its customers could become the pharmaceutical committees deciding which trials deserve funding in the first place.
CLINICAL AI
2. Abridge Puts Health Systems' Own Care Pathways Inside Its AI Assistant
Abridge is bringing hospital-specific clinical pathways into its AI Assistant, helping clinicians access local guidance alongside published medical evidence. Image: Abridge.
On November 12, Abridge introduced local clinical pathways into the Abridge Assistant. Clinicians can now access their health system's own treatment guidance alongside published medical literature, matched to the patient they are treating.
The details:
How it works: The Assistant uses patient context to surface relevant hospital protocols, with links to original documents. Clinicians remain responsible for reviewing and applying the guidance.
Scale: Abridge reports adoption across more than 300 enterprise health systems representing over 250 million patients. Its platform is expected to support more than 120 million clinical encounters this year.
Deployment: Existing Abridge customers can enable the feature, bringing hospital-specific care guidance directly into established workflows.
The Signal: Ambient AI is moving beyond documentation into clinical decision support. By combining medical literature with hospital-specific protocols, Abridge is competing to become the clinician's first stop for answers. The advantage may increasingly belong to whoever controls the institutional knowledge clinicians rely on every day.
HOSPITAL OPS
3. Ohio State and Microsoft Sign a Five-Year Deal to Build a Smart Hospital
Ohio State Wexner Medical Center and Microsoft announced a five-year partnership to modernize hospital infrastructure, integrate clinical data and expand AI-powered care. Image: Ohio State Wexner Medical Center.
The Ohio State University Wexner Medical Center and Microsoft announced a five-year partnership on November 10 to modernize hospital infrastructure, connect clinical and operational data, and expand AI across care delivery and research.
The details:
Cloud migration: Approximately 70–80% of storage and computing workloads will move to Azure, including imaging and pathology. The electronic health record will also receive an Azure-based backup.
Smart infrastructure: Azure-powered IoT systems already support energy and resource management at two facilities. Microsoft Fabric and OneLake will help unify data for forecasting surgical demand, staffing and operating room use.
Clinical AI: Dragon Copilot already assists with clinical documentation. The partners are exploring AI-supported tumor boards combining imaging, pathology, genomics and patient history.
The Signal: This goes beyond a conventional cloud migration. Ohio State is bringing hospital infrastructure, clinical records and research data onto a more connected platform. The potential gains in efficiency and resilience are significant, but so is the dependence on one technology partner.
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
Orakl's real-world validation: Peer-reviewed SCOPE results, prospective Sanofi asset predictions and evidence that its forecasts actually change trial decisions.
Abridge's clinical adoption: Which hospitals activate local pathways, how clinicians use them, and whether competing assistants introduce similar capabilities.
Ohio State's implementation: Migration progress, EHR backup testing, operational forecasting results and whether other hospitals follow its approach.
💰 FOLLOW THE MONEY
The deals:
Mosaic Intelligence Labs, $47M: Two seed rounds led by 8VC and Fundomo to develop sensing catheters and real-time vascular imaging.
Orakl Oncology, $34M: Series A to expand patient-derived tumor models and AI-powered cancer trial forecasting.
Nanopath, $25M: Series B funding, including $2 million in grants, to advance its 15-minute molecular diagnostic toward FDA review.
Duet, $15M: Series A led by Kairos to expand its nurse practitioner-led primary care network and supporting AI tools.
Francis Medical, Undisclosed: JJDC-led financing to support Vanquish commercialization and clinical evidence generation.
The pattern: Capital is moving toward companies that own the instruments, laboratories and clinical networks producing valuable data. AI becomes more defensible when competitors cannot easily replicate its inputs.
📆 UPCOMING HEALTHTECH EVENTS
HLTH USA 2026: November 15–18 | Las Vegas, USA. Major digital health gathering featuring AI, revenue cycle technology and connected care.
RSNA 2026: November 29–December 3 | Chicago, USA. A major showcase for medical imaging, diagnostics and cloud-based imaging infrastructure.
GIANT Health 2026: December 7–8 | London, UK. Digital health innovation, AI adoption and healthcare technology regulation.
🛠️ Trending HealthTech AI Tools
TytoCare AI Care Enablement Platform: Launched November 12, combining remote examinations, connected devices and AI-supported patient monitoring. Initial focus: COPD, with heart failure and oncology to follow.
Malaffi AI Physician Assistant: Announced November 10 in Abu Dhabi. Uses the emirate's health information exchange to summarize patient histories and support clinical queries across more than 14 million patient records.
ALIS MCP Connector for Claude: Announced November 12, enabling permission-controlled, read-only access to assisted living and memory care data through Claude.
🛠️ Trending HealthTech AI Startups
Mosaic Intelligence Labs: Emerging from stealth with $47 million, the San Francisco startup is developing sensing endovascular devices that reconstruct vessel anatomy in real time and support robotic procedures.
Nanopath: The Cambridge, Massachusetts company secured $25 million to advance its amplification-free molecular diagnostics platform, starting with a 15-minute point-of-care vaginitis test.
Duet: Raised $15 million to grow its network of more than 130 nurse practitioner-owned clinics across 21 U.S. states, using AI to identify care gaps and prepare clinicians for visits.
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
How tumor organoids and AI could improve oncology trial decisions, what early evidence supports, and whether pharmaceutical companies will pay for predictive trial forecasts.
Why hospital-specific knowledge is becoming a competitive asset, how Abridge compares with established clinical reference tools, and the governance questions ahead.
What a large-scale hospital cloud migration means for resilience, operational efficiency, AI adoption and long-term technology dependence.
Where will proprietary data create the most value in HealthTech AI over the next three years?
That's it for today!
Orakl is growing tumors to predict clinical trial outcomes. Abridge is putting hospital-specific knowledge into clinical workflows. Ohio State is building the data infrastructure for a more connected hospital.
The common thread is clear: healthcare AI is moving from competing on models to competing on access to valuable data.
But access alone is not enough. The companies that win will need to show that their proprietary information leads to better clinical decisions, stronger evidence and measurable improvements in care.
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal
